DexCom, Inc.

DexCom, Inc.

DXCMNYSE / NASDAQHealthcareLarge cap

$79.32-$0.87 (-1.1%)

Last close · Data as of Nov 20, 2026

Market cap
$28.0B
P/E
33.5x
EV / EBITDA
21.0x
Revenue
$4.7B
Net margin
17.9%
ROCE
21.7%

+35.8% over the last year

DexCom, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-7.5%
3M
-12.1%
6M
+11.0%
1Y
+35.8%
5Y
-50.5%

52-week range

Day change -$0.87 (-1.1%) from $80 to $79 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in DXCM, bought on each weekday since 2021.

News & filings

What DexCom filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 60.5 times interest costs.

Concerns (1)

  • The P/E of 33.5 is 97% above the peer median of 17.0.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

Read moreShow less

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
390.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$28.0B
P/E
33.5x
P/B
10.2x
EV / EBITDA
21.0x
EV / Sales
6.1x
P/S
6.0x
52-week high
$92.34
52-week low
$57.56

Profitability

Operating margin
19.6%
Net margin
17.9%
EBITDA margin
29.1%
ROE
30.5%
ROCE
21.7%
ROA
13.2%
Asset turnover
0.74

Growth

Revenue
$4.7B
Revenue growth, 1Y
15.6%
Revenue CAGR, 3Y
17.0%
Net profit growth, 1Y
45.1%
Free cash flow
$1.1B

Solvency

Current ratio
1.88
Debt / Equity
0.51
Debt / Assets
0.22
CFO / Net profit
1.72
Cash / Market cap
3.3%

Where the revenue went

Of every $100 of FY2025 revenue, $18 was left as net income.

DexCom, Inc. income statement flow, FY2025
DexCom, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.9B
RevenueGross profit$2.8B
Gross profitResearch and development$599.1M
Gross profitSelling, general and administrative$1.3B
Gross profitOther operating expenses$0.00
Gross profitOperating income$911.8M
Operating incomePretax income$911.8M
Interest and other incomePretax income$176.6M
Pretax incomeTax and other$252.1M
Pretax incomeNet income$836.3M

Revenue and net profit

Revenue grew 15.6% in FY2025; net profit is the dashed line.

DexCom, Inc. revenue and net profit by fiscal year
DexCom, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.9B$341.2M
FY2023$3.6B$541.5M
FY2024$4.0B$576.2M
FY2025$4.7B$836.3M

Cash flows

FY2025: $1.4B from operations, $1.1B free after investment (dashed).

DexCom, Inc. operating and free cash flow by fiscal year
DexCom, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$669.5M$304.7M
FY2023$748.5M$511.9M
FY2024$989.5M$630.7M
FY2025$1.4B$1.1B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.7B+15.6%1Y
EBITDA
$1.4B+43.7%1Y
Net profit
$836.3M+45.1%1Y
Cash from operations
$1.4B+45.6%1Y
Free cash flow
$1.1B+70.8%1Y
Revenue CAGR, 3Y
17.0%
Net profit CAGR, 3Y
34.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.7B$1.4B$836.3M$1.1B30.5%+15.6%+45.1%

Monthly returns

Month-by-month returns of DXCM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$6.3B
Liabilities$3.6B
Equity$2.7B
Paid-in capital$2.3B
Retained earnings$2.4B
Treasury stock$2.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; DXCM highlighted.

P/E against peers

DXCM trades at 33.5x earnings against a peer median of 17.0x (a 97% premium).

Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
DexCom, Inc.DXCMthis companyP/E ↑ premium$28.0B33.5x10.2x30.5%21.0x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
GE HealthCare Technologies Inc.GEHC$29.0B13.9x2.8x20.1%9.2x
Biogen Inc.BIIB$29.0B22.4x1.6x7.1%12.5x
ResMed Inc.RMD$28.2B20.1x4.7x23.5%14.5x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
Peer median—17.0x4.7x13.6%12.5x

Year-to-date ROI

DXCM since 1 January, against earlier years.

Historical volatility

DXCM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

DexCom, Inc. operating margin by fiscal year
DexCom, Inc. operating margin by fiscal year
DateOperating margin
FY202213.4%
FY202316.5%
FY202414.9%
FY202519.6%
LineFY2025
Cost of revenueCost Of Revenue$1.9B
Gross profitGross Profit$2.8B
Operating expensesOperating Expense$1.9B
Research and developmentResearch And Development$599.1M
Selling, general and administrativeSelling General And Administration$1.3B
Depreciation and amortisationDepreciation And Amortization In Income Statement—
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement—
Amortization—
Amortisation of intangiblesAmortization Of Intangibles Income Statement—
Total expensesTotal Expenses$3.8B
Pretax incomePretax Income$1.1B

Learn while you research

Academy chapters picked for DexCom, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 33.5, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →